CytomX Therapeutics Income Statement (2014-2026) | CTMX

Income Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
9.19M11.13M9.04M12.85M11.15M20.12M23.50M24.72M26.38M26.61M41.46M25.11M33.43M38.09M50.92M18.66M5.96M0.66M10.26M1.42M
Operating items
Research & Development (Quarter)
29.14M36.58M30.56M31.16M30.37M19.56M21.18M20.67M16.45M19.39M22.05M25.17M21.37M14.79M18.87M13.32M15.30M21.23M19.24M17.60M
Selling, General & Administrative (Quarter)
11.09M9.46M10.54M11.75M10.49M10.07M7.98M7.40M6.81M7.83M7.75M8.39M7.95M5.62M9.43M6.62M6.43M7.36M10.69M7.60M
Operating Expenses (Quarter)
40.23M46.03M41.10M42.91M40.86M29.63M29.15M28.07M23.26M27.21M29.81M33.57M29.32M20.41M28.30M19.94M21.73M28.59M29.93M25.20M
Operating Income (Quarter)
-31.04M-34.90M-32.06M-30.05M-29.71M-9.51M-5.65M-3.35M3.12M-0.61M11.66M-8.45M4.11M17.68M22.62M-1.29M-15.77M-27.93M-19.67M-23.78M
EBIT (Quarter)
-31.04M-34.90M-32.06M-30.05M-29.71M-9.51M-5.65M-3.35M3.12M-0.61M11.66M-8.45M4.11M17.68M22.62M-1.29M-15.77M-27.93M-19.67M-23.78M
Non-operating items
Interest & Investment Income (Quarter)
0.07M0.07M0.07M0.26M0.62M0.73M2.33M2.31M2.70M2.50M2.19M1.97M1.69M1.28M0.95M1.18M1.59M1.48M1.49M3.16M
Other Non Operating Income (Quarter)
-0.01M0.01M0.01M0.30M0.03M0.00M0.01M-0.05M-0.01M0.01M-0.01M-0.00M-0.01M-0.02M0.01M0.02M0.01M-0.39M-0.01M0.02M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M5.82M1.91M13.84M-6.48M5.80M18.94M23.59M-0.09M-14.17M-26.46M-18.19M-20.61M
Tax Provisions (Quarter)
2.82M1.07M0.05M0.05M0.06M0.06M0.06M0.06M0.06M-3.78M0.06M0.06M
Profit After Tax (Quarter)
-30.95M-34.82M-31.98M-29.50M-28.70M-8.78M-3.31M-1.09M2.89M0.84M13.79M-6.53M5.78M18.88M23.50M-0.15M-14.23M-26.51M-18.26M-20.96M
Income from Non-Controlling Interests (Quarter)
0.04M-0.29M-0.68M-0.24M0.37M0.81M0.02M0.01M-0.10M0.16M-0.10M0.01M0.04M-0.01M-0.03M0.03M0.07M-0.01M-0.30M
Income from Continuing Operations (Quarter)
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M2.99M0.84M13.79M-6.53M5.74M18.88M23.52M-0.15M-14.23M-22.67M-18.25M-20.67M
Consolidated Net Income (Quarter)
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M2.99M0.84M13.79M-6.53M5.74M18.88M23.52M-0.15M-14.23M-22.67M-18.25M-20.67M
Income towards Parent Company (Quarter)
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M2.99M0.84M13.79M-6.53M5.74M18.88M23.52M-0.15M-14.23M-22.67M-18.25M-20.67M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-30.98M-34.82M-31.98M-29.50M-29.06M-8.78M-3.31M-1.09M2.99M0.84M13.79M-6.53M5.74M18.88M23.52M-0.15M-14.23M-22.67M-18.25M-20.67M
Additional items
EPS (Basic) (Quarter)
-0.48-0.54-0.49-0.45-0.44-0.13-0.05-0.020.040.010.17-0.080.070.220.270.00-0.09-0.16-0.10-0.09
EPS (Diluted) (Quarter)
-0.48-0.54-0.49-0.45-0.44-0.13-0.05-0.020.040.010.17-0.080.070.220.270.00-0.09-0.16-0.10-0.09
Shares Outstanding (Quarter)
65.21M64.15M65.39M65.54M65.91M65.74M66.25M66.54M80.73M73.81M82.03M84.88M85.09M84.44M87.12M129.08M165.00M137.94M177.27M218.94M
Shares Outstanding (Diluted) (Quarter)
65.21M64.15M65.39M65.54M65.91M65.74M66.25M66.54M80.99M73.81M82.63M84.88M85.20M84.75M87.15M129.08M165.00M137.94M177.27M218.94M
Shares Outstanding (Entity) (Quarter)
65.25M65.39M65.40M65.76M65.95M66.23M66.34M66.77M66.87M67.31M68.14M78.12M78.26M80.10M80.62M129.08M169.44M137.94M177.27M217.90M
EBITDA (Quarter)
-31.04M-34.90M-32.06M-30.05M-29.71M-9.51M-5.65M-3.35M3.12M-0.61M11.66M-8.45M4.11M17.68M22.62M-1.29M-15.77M-27.93M-19.67M-23.78M
Interest Expenses (Quarter)
1.27M1.31M0.92M1.16M0.80M2.30M2.80M175.45M3.90M4.00M4.10M162.11M5.10M5.10M5.00M0.03M5.70M
Tax Rate (Quarter)
48.55%56.09%0.35%-0.79%1.05%0.33%0.26%-69.23%-0.41%14.30%-0.32%-0.29%